These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 29573975)
21. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098 [TBL] [Abstract][Full Text] [Related]
22. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855 [TBL] [Abstract][Full Text] [Related]
23. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311 [TBL] [Abstract][Full Text] [Related]
24. The cardiovascular polypill: clinical data and ongoing studies. Castellano JM; Bueno H; Fuster V Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391 [TBL] [Abstract][Full Text] [Related]
25. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe. Grigorian-Shamagian L; Edel K; Esteve-Pastor MA; Aceña Á; Silva C; Delgado-Silva J; Ntaios G; Demerouti E; Brotons C Front Cardiovasc Med; 2021; 8():663361. PubMed ID: 34504874 [TBL] [Abstract][Full Text] [Related]
26. Polypill: quo vadis? Muscente F; De Caterina R J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194 [TBL] [Abstract][Full Text] [Related]
28. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial. Sadeghi M; Hoseini SG; Nateghi A; Sarrafzadegan N; Mansoorian M; Najafian J; Roohafza H Curr Probl Cardiol; 2022 Jun; 47(6):100872. PubMed ID: 34016484 [TBL] [Abstract][Full Text] [Related]
29. The polypill: a potential global solution to cardiovascular disease. Nguyen C; Cheng-Lai A Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668 [TBL] [Abstract][Full Text] [Related]
31. Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? Selak V; Webster R Ther Adv Drug Saf; 2018 Feb; 9(2):157-162. PubMed ID: 29387338 [TBL] [Abstract][Full Text] [Related]
32. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750 [TBL] [Abstract][Full Text] [Related]
33. The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R; Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247 [TBL] [Abstract][Full Text] [Related]
34. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Carey KM; Comee MR; Donovan JL; Kanaan AO Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437 [TBL] [Abstract][Full Text] [Related]
36. Polypill, hypertension and medication adherence: The solution strategy? Cimmaruta D; Lombardi N; Borghi C; Rosano G; Rossi F; Mugelli A Int J Cardiol; 2018 Feb; 252():181-186. PubMed ID: 29180263 [TBL] [Abstract][Full Text] [Related]
37. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058 [TBL] [Abstract][Full Text] [Related]
38. The polypill approach - An innovative strategy to improve cardiovascular health in Europe. Fuster V; Gambús F; Patriciello A; Hamrin M; Grobbee DE BMC Pharmacol Toxicol; 2017 Feb; 18(1):10. PubMed ID: 28166827 [TBL] [Abstract][Full Text] [Related]